Meniu
Asmeninė anketa Prisijungimas ir registracija
Atgal Pagrindinis » Skaniai ir Paprastai: Receptai Kiekvienam » Medical Health » 2020 » Spalio » 22

COVID-19 vaccine trials cannot tell us if they will save lives

COVID-19 vaccine trials cannot tell us if they will save lives

Vaccines are being hailed as the solution to the COVID-19 pandemic, but the vaccine trials currently underway are not designed to tell us if they will save lives, reports Peter Doshi, Associate Editor at The BMJ today.

Several COVID-19 vaccine trials are now in their most advanced (phase 3) stage, but what will it mean exactly when a vaccine is declared "effective"?

Many may assume that successful phase 3 studies will mean we have a proven way of keeping people from getting very sick and dying from COVID-19. And a robust way to interrupt viral transmission.

Yet the current phase 3 trials are not actually set up to prove either, says Doshi.

"None of the trials currently underway are designed to detect a reduction in any serious outcome such as hospitalisations, intensive care use, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus," he writes.

He explains that all ongoing phase 3 trials for which details have been released are evaluating mild, not severe, disease—and they will be able to report final results once around 150 participants develop symptoms.

In Pfizer and Moderna's trials, for example, individuals with only a cough and positive lab test would bring those trials one event closer to their completion.

Yet Doshi argues that vaccine manufacturers have done little to dispel the notion that severe COVID-19 was what was being assessed.

Moderna, for example, called hospitalisations a "key secondary endpoint" in statements to the media. But Tal Zaks, Chief Medical Officer at Moderna, told The BMJ that their trial lacks adequate statistical power to assess that endpoint.

Part of the reason may be numbers, says Doshi. Because most people with symptomatic COVID-19 infections experience only mild symptoms, even trials involving 30,000 or more patients would turn up relatively few cases of severe disease.

"Hospitalisations and deaths from COVID-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30,000 people," he adds. "The same is true regarding whether it can save lives or prevent transmission: the trials are not designed to find out."

Zaks confirms that Moderna's trial will not demonstrate prevention of hospitalisation because the size and duration of the trial would need to be vastly increased to collect the necessary data. "Neither of these I think are acceptable in the current public need for knowing expeditiously that a vaccine works," he told The BMJ.

Moderna's trial is designed to find out if the vaccine can prevent COVID-19 disease, says Zaks. Like Pfizer and Johnson and Johnson, Moderna has designed its study to detect a relative risk reduction of at least 30% in participants developing lab-confirmed COVID-19, consistent with FDA and international guidance.

Zaks also points to influenza vaccines, saying they protect against severe disease better than mild disease. "To Moderna, it's the same for COVID-19: if their vaccine is shown to reduce symptomatic COVID-19, they will feel confident it also protects against serious outcomes," Doshi writes.

But Doshi raises another important issue—that few or perhaps none of the current vaccine trials appear to be designed to find out whether there is a benefit in the elderly, despite their obvious vulnerability to COVID-19.

If the frail elderly are not enrolled into vaccine trials in sufficient numbers to determine whether there is a reduction in cases in this population, "there can be little basis for assuming any benefit against hospitalisation or mortality," he warns.

Doshi says that we still have time to advocate for changes to ensure the ongoing trials address the questions that most need answering.

For example, why children, immunocompromised people, and pregnant women have largely been excluded; whether the right primary endpoint has been chosen; whether safety is being adequately evaluated; and whether gaps in our understanding of how our immune system responds to COVID-19 are being addressed.

"The COVID-19 vaccine trials may not have been designed with our input, but it is not too late to have our say and adjust their course. With stakes this high, we need all eyes on deck," he argues.

  • by British Medical Journal
  • SARS-CoV-2 (shown here in an electron microscopy image). Credit: National Institute of Allergy and Infectious Diseases, NIH
Pasaulio naujienas kitaip... skaitykite Paranormal Telegram, FB ir X(twitter) kanale

...kadangi jau perskaitėte šį straipsnį iki pabaigos, prašome Jus prisidėti prie šio darbo. Skaitykite „Paranormal.lt“ ir toliau, skirdami kad ir nedidelę paramos sumą. Paremti galite Paypal arba SMS. Kaip tai padaryti? Iš anksto dėkojame už paramą! Nepamirškite pasidalinti patikusiais tekstais su savo draugais ir pažįstamais.

Turite savo nuomone, tapk autoriumi, prisijunk ir rašykite bloge. Dalinkitės receptais, sveikatos patarimais, nutikimais, susidūrėte su nekasdieniškais reiškiniais. Galite išversti iš užsienio kalbos, talpinkite su nuoroda. Laukiame Jūsų straipsnių, naujienų, apžvalgų ar istorijų!

Niekas neišdrįso palikti komentaro.
Būkite pirmi, kurie pasidalins savo nuomonėmis su kitais.
avatar

Nemokami skelbimai

TAIP PAT SKAITYKITE:
2025-10-08 laikas 09:34 Receptai Vištienos kepsnys su pievagrybių padažu: skanus receptas, nauda sveikatai ir mitybos patarimai

Sultingas vištienos kepsnys su pievagrybių padažu – lengvas, bet prabangus receptas šeimai. Sužinokite apie naudą: baltymai raumenims, selenas imunui, skaidulos virškinimui. Kalorijos: 450 kcal porcijoje. Kaip įsisavinamo...

Skaityti daugiau

2025-10-08 laikas 08:41 Receptai Traškus faršo šnicelis su juoda duona: tradicinis receptas, sveikatos nauda ir mitybos patarimai

Traškus faršo šnicelis su juoda duona – klasikinis lietuviškas receptas, kupinas vaikystės prisiminimų. Sužinokite apie naudą: baltymai raumenims, skaidulos virškinimui. Kalorijos: 400 kcal po...

Skaityti daugiau

2025-10-08 laikas 08:19 Receptai Prabangūs lietiniai blynai su maskarpone ir baltu šokoladu: receptas, nauda sveikatai ir mitybos patarimai
Prabangūs lietiniai blynai su maskarpone ir baltu šokoladu – lengvas receptas, kuris džiugina skonį ir sveikatą. Sužinokite apie naudą: kalcis kaulams, energija iš baltymų. Kalorijos: 350 kcal porcijoje. Kaip įsisavinamos medžiago...

Skaityti daugiau

2025-10-08 laikas 10:02 Rūgštinti obuoliai: nauda sveikatai, įsisavinimas, rizikos ir tradiciniai receptai

Rūgštinti obuoliai – ukrainietiškas probiotinis hitas: gerina virškinimą (probiotikai +30% mikrofloros), stiprina imuną (vitaminas C +25% absorbcija), palaiko širdį (pektinai mažina LDL 10%). Paaiškiname įsisavinimą (žarnyne per 1–2 va...

Skaityti daugiau

2025-10-08 laikas 09:42 Vaistinis valerijonas: nauda sveikatai, įsisavinimas, žala ir tradiciniai receptai

Vaistinis valerijonas – natūralus ramintuvas: gydo nemigą, nerimą, širdies neurozę, padeda menopauzėje. Sužinokite naudą (GABA modulisacija), įsisavinimą (greitas žarnyne), žalą (galvos skausmas, priklausomybė) i...

Skaityti daugiau

2025-10-08 laikas 07:37 Kur dingsta uodai žiemą? Išsami vadovas apie kraujasiurbių žiemojimą, rūšis ir prevenciją
Žiemą uodai dingsta, bet ne amžiams – jie slepiasi diapauzės būsenoje ar kiaušinėlių pavidalu, laukdami pavasario. Šiame išsamiame straipsnyje aptariame uodų gyvenimo ciklą, skirtingų rūšių žiemojimo strategijas ir mokslinius faktus iš tarptautinių š...

Skaityti daugiau

2025-10-07 laikas 18:54 Vienoje teisme teisiami migrantai paaugliai už mokytojos išprievartavimą ir šantažavimą
Trys pagrindiniai kaltinamieji yra 15-metis irakietis, 17-metis rumunas ir 15-metis afganistanietis, kurie kaltinami kelis mėnesius trukusiu teroro kampanija prieš mokytoją.

Skaityti daugiau

2025-10-07 laikas 18:39 Graikija ketina sumažinti prieglobsčio išmokas ir nutraukti būsto subsidijas pabėgėliams
Kiekvienas, kuriam šioje šalyje suteiktas prieglobstis, nebegalės gyventi iš išmokų, mokamų Europos ir Graikijos mokesčių mokėtojų sąskaita

Skaityti daugiau